Author

Alan Loh Ho

Memorial Sloan Kettering Cancer CenterORCID 0000-0002-6885-3742Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1

Frequent Co-Authors

Bin XuiD· 1 shared Elisa de StanchinaiD· 1 shared Eric Jeffrey ShermaniD· 1 shared Gnana Prakasam KrishnamoorthyiD· 1 shared James A. FaginiD· 1 shared Jeffrey A. KnaufiD· 1 shared Jena D. FrenchiD· 1 shared Jian Jun JiniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bin XuORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyJournal of Clinical InvestigationPeer-reviewedAug 19, 2025

Loss of tumor cell MHC Class II drives insensitivity of BRAF-mutant anaplastic thyroid cancers to MAPK inhibitors

Vera Tiedje, Jillian Greenberg, Tianyue Qin…·James A. Fagin

This study shows that loss of MHC Class II in BRAF-mutant anaplastic thyroid cancers leads to resistance to MAPK inhibitors by reducing CD4+ T-cell activation.

8 citations

mousebulk RNA-seq

𝕏 PostBluesky